News

SHARE initiative releases consensus-based JDM management recommendations

View on the News

Accurate patient characterization is needed

The consensus-based recommendations for the management of juvenile dermatomyositis published in Annals of Rheumatic Diseases again highlight the ability of the European and Canadian investigators to work together and pool the information from a large number of centers. Similar efforts to pool data and encourage the development of protocols to optimize care are occurring in the United States under the auspices of CARRA (the Childhood Arthritis and Rheumatology Research Alliance).

These working groups represent an important first step toward standardizing optimal care for children with rheumatic diseases. However, the protocols put forth by both groups suffer from failure to address the diversity of presentations within their diseases and a resultant lack of specificity in their recommendations. The authors of these guidelines make specific recommendations regarding diagnosis, but these fail to encompass the range of weakness that may be present initially. Is it truly appropriate to bolus every child diagnosed with dermatomyositis with high-dose corticosteroids and begin methotrexate? No mention is made of the hypertension, pancreatitis, or systemic infection that might result.

The guidelines and protocols being promulgated in pediatric rheumatology continue to suffer from the grouping of children with diverse disease presentations and probably diverse diseases under a single diagnosis. Charles Spencer and colleagues described the highly variable course of juvenile dermatomyositis and the presence of distinct subsets of patients more than 30 years ago (J Pediatr. 1984 Sep;105[3]:399-408), but this diversity is not reflected in the current protocol. Methods for better characterizing our patients based on gene activation and cytokine profiles have been developed. More effort should be placed on accurate characterization of our patients with many diseases before we attempt to treat them all the same way.

Thomas J.A. Lehman, MD, is chief of the division of pediatric rheumatology at the Hospital for Special Surgery, and professor of clinical pediatrics at Weill Medical Center, Cornell University, New York. He has no relevant disclosures.


 

FROM ANNALS OF THE RHEUMATIC DISEASES

References

Early and aggressive therapy may prevent or stabilize organ damage and disease-related complications in patients with juvenile dermatomyositis, according to new consensus-based recommendations for the management of the disorder.

Overall, the recommendations – a project of the Single Hub and Access Point for Pediatric Rheumatology in Europe (SHARE) initiative – include 7 overarching principles, 33 recommendations on diagnosis, and 19 recommendations on therapy that were accepted with greater than 80% agreement among experts. The recommendations, which address the assessment of skin, muscle, and major organ involvement and treatment suggestions at disease onset and in refractory cases, fill a void in the area of evidence-based guidelines for this rare disease within the group of pediatric rheumatic diseases, according to Felicitas Bellutti Enders, MD, of University Medical Center Utrecht (the Netherlands) and her colleagues.

A patient with juvenile dermatomyositis shows Gottron's papules, erythematous to violaceous raised papules overlying the metacarpal and interphalangeal joints. Elizabeth M. Dugan, Adam M. Huber, Frederick W. Miller, Lisa G. Rider / CC-BY-SA-3.0

A patient with juvenile dermatomyositis shows Gottron's papules, erythematous to violaceous raised papules overlying the metacarpal and interphalangeal joints.

“Clear recommendations can help clinicians in the care of patients with JDM [juvenile dermatomyositis] as no international consensus regarding diagnosis and treatment is currently available and management therefore varies,” they wrote (Ann Rheum Dis. 2016 Aug 11. doi: 10.1136/annrheumdis-2016-209247).

The consensus committee, including 19 experienced pediatric rheumatologists and 2 experts in pediatric exercise physiology and physical therapy, developed recommendations based on a validated systematic literature review. The recommendations were evaluated by an online survey and then discussed at two subsequent consensus meetings.

The overarching principles accepted by more than 80% of respondents (100% in all but number 4 below), hold that:

1) All children with suspected idiopathic inflammatory myopathies should be referred to a specialized center.

2) High-risk patients need immediate/urgent referral to a specialized center.

3) Patient-/parent-reported outcomes measures are helpful when assessing disease activity and should be used at diagnosis and during disease monitoring.

4) Validated tools such as the Childhood Health Assessment Questionnaire, patient/parent visual analog scale and Juvenile Dermatomyositis Multi-dimensional Assessment Report should be used to measure health status.

5) All children with JDM should have disease activity (muscle, skin, major organ) assessed regularly in a standardized way, using tools such as the Disease Activity Score.

6) All children with JDM should have disease damage assessed at least yearly using a standardized disease damage measure, such as the Myositis Damage index.

7) All patients with JDM should have the opportunity to be registered within a research registry/repository such as the Euromyositis registry.

The consensus process also yielded both general and specific recommendations for diagnosis and management – also with 100% agreement in almost all cases – addressing investigations to consider in all those with a JDM diagnosis (muscle enzymes, full blood count, renal function and liver function tests, and infection screen – to name a few), ways that MRI can be used (both for diagnosis and disease activity monitoring), the use of muscle biopsy (use in all cases involving atypical presentation), and assessment of calcinosis and skin, lung, and cardiac involvement.

Treatment recommendations address sun protection (encourage routine use of sunblock), exercise (should be safe and appropriate and monitored by a physiotherapist), corticosteroid use (administer systematically either orally or intravenously in moderate to severe JDM and wean as the patient shows clinical improvement), use of intravenous immunoglobulin (a useful adjunct for resistant disease, especially when skin features are prominent), and the use of anti–tumor necrosis factor therapies (consider in refractory disease; infliximab or adalimumab are favored over etanercept), as well as other treatments.

The recommendations state that while there is no high-level evidence of when to stop therapy, consideration may be given to withdrawing treatment if a patient has been off steroids and in remission on methotrexate or an alternative disease-modifying antirheumatic drug [DMARD] for at least 1 year.

The management of JDM is complex and warrants a multidisciplinary approach, involving physiotherapists, specialist nurses, pediatric rheumatologists, and other specialists as needed, the authors wrote, noting that the mainstay of therapy is high-dose corticosteroids initially in combination with DMARDS.

However, the evidence base for treatment is limited and “often confined to small case-controlled studies, with the exception of two randomized controlled trials,” they said.

Similarly, there is no high-level evidence regarding when to stop immunosuppressive therapy, but the expert group suggested considering the withdrawal of methotrexate or alternative DMARD once the patient is in remission and off steroids for a minimum of 1 year.

The authors concluded that “this SHARE initiative is based on expert opinion informed by the best available evidence and provides recommendations ... with a view to improving the outcome for patients with JDM in Europe.

Pages

Recommended Reading

Updated Behçet’s disease recommendations expand biologic treatment
MDedge Rheumatology
European ANCA-associated vasculitis guidance gets first makeover since 2009
MDedge Rheumatology
Actemra may reduce scleroderma skin thickening
MDedge Rheumatology
VIDEO: TNF inhibitors improved refractory skin disease in juvenile dermatomyositis
MDedge Rheumatology
HCQ eye toxicity needs experience to assess
MDedge Rheumatology
Mechanism proposed for microvascular thrombosis in thrombotic thrombocytopenic purpura
MDedge Rheumatology
FDA accepting comments on draft guidelines on compounding law
MDedge Rheumatology
Psoriasiform eruptions in Kawasaki disease reveal distinct phenotype
MDedge Rheumatology
Teams boost confidence in IPF diagnoses
MDedge Rheumatology
Benefits, challenges emerge in evolution of rheumatology-dermatology clinics
MDedge Rheumatology